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Phyllanthus urinaria Linnea (Euphorbiaceae) is one of the traditional medicinal plants widely used by oriental people to treat
various diseases. We have previously demonstrated that the acetone extract of P. urinaria inhibits herpes simplex virus type 2
(HSV-2) but not HSV-1 infection. In a continuing eﬀort to clarify the antiviral mechanisms of P. urinaria, we isolated the pure
compound excoecarianin from the whole plant of P. urinaria through acetone extraction, and investigated its anti-HSV-1 and
HSV-2 activities. Our results indicated that excoecarianin protected Vero cells from HSV-2 but not HSV-1 infection, and its 50%
inhibitory concentration (IC50)w a s1 . 4± 0.1μM. The antiviraleﬀective concentration of excoecarianin did not aﬀect the viability
or the morphology of Vero cells. Although excoecarianin inhibited HSV-2 infection, the inhibitory eﬀect, however, was most
prominentwhen excoecarianin wasconcurrently added with the virus. Pretreatment ofVero cells with excoecarianin with removal
of the drug prior to infection did not yield any antiviral eﬀects, and the sameobservation was made for post viral entry treatment.
Subsequent studies revealed that excoecarianin inactivated HSV-2 virus particles to prevent viral infection. A synergistic antiviral
eﬀect against HSV-2 was also observed when Vero cells were treated with a combination of acyclovir (ACV) and excoecarianin.
These results suggested that excoecarianin merits to be further explored as an entry inhibitor against HSV-2 and could potentially
be investigated for combinatorial drug treatment with nucleoside analogues such as ACV in therapeutic management of HSV-2
infection.
1.Introduction
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)
are two species of the Herpesviridae family, which consists
of large DNA-enveloped viruses. While HSV-1 is more fre-
quently associated with oral–facial mucocutaneous lesions
(cold sores and fever blisters), HSV-2 is more commonly as-
sociated with genital herpes. The two viruses can cause a
variety of diseases, which in certain cases, may lead to com-
plications, especially in immunocompromised patients. Her-
pes viruses usually produce lifelong infections, and recurrent
infection may occur upon viral reactivation through stimuli
such as sunlight, stress and weakened immunity.
Nucleoside analogs such as acyclovir (ACV) are the pri-
mary candidates used to treat HSV infections. Although
some non-nucleoside inhibitors of herpesviruses have been
developed [1–3], few of them are oﬃcially approved for
HSV therapy [4, 5]. The lack of approved therapeutics and
the emergence of ACV-resistant HSV strains have made the
management of HSV infection a challenge, particularly in
immunocompromised patients. In fact, previous reports
have indicated that ACV-resistant HSV is more frequently2 Evidence-Based Complementary and Alternative Medicine
identiﬁed in immunocompromised individuals rather than
in those who are immunocompetent [6, 7]. Consequently,
there is still a need to search for novel and more eﬀective
antiviral agents to preventand/or to treat HSVinfections [8–
10].
Many naturally occurring plants, either as extracts or as
pure compounds, have been reported to exhibit antiviral ac-
tivities [11–14], indicating that plant materials may serve as
a source for the discovery of antiviral agents. Phyllanthus
urinaria Linnea (Euphorbiaceae) is a traditional medicinal
plant that is widely used in Eastern Asia to treat a variety of
diseases. The pharmacological activities of P. urinaria have
been well documented in literature [15–36], and include
antiviral activities [37–43] as well.
In our previous studies, we showed that the acetone, eth-
anol and methanol extracts of P. urinaria inhibited HSV
infections in vitro [44]. Further isolation of gemin D, gerani-
i n ,h i p p o m a n i nAa n d1 ,3 ,4 ,6 - t e t r a - O-galloyl-β-d-glucose
from the acetone extract of P. urinaria was found to suppress
HSV infections at diﬀerent magnitudes of potency [45, 46].
In a continuing eﬀort to clarify the antiviral proﬁle of P.
urinaria, weisolatedanotherpurecompound,excoecarianin,
fromthewholeplantofP.urinaria byacetoneextraction,and
investigated its anti-HSV-1 and HSV-2 activities.
2.Methods
2.1.Plant Materials. The plant P. urinaria was collectedfrom
Ping-Tung County and was authenticated using morpholog-
ical and anatomical techniques. A voucher specimen, with
reference number of KMU-HL-PUL 2002, was deposited at
the Herbarium of the Graduate Institute of Natural Products
of Kaohsiung Medical University.
2.2. Isolation of Excoecarianin from P. urinaria . Total 9.5 kg
of fresh whole P. urinaria plant was cut into small pieces
and extracted with acetone–water (4:1, v/v). The extract
was concentrated under reduced pressure and then ﬁltered.
The ﬁltrate was subsequently eluted with water–methanol
and then with water–acetone through Sephadex LH-20 to
give four fractions. Fraction 4 was further chromatographed
on Sephadex LH-20, MCI-gel CHP 209, Fuji gel ODSG3,
SephadexLH-20and BondapackC18/porasilBtoget101mg
of excoecarianin (Figure 1) with the yield of 0.001%. The
structure and purity (>95%) of excoecarianin were deter-
mined by spectroscopic and physical data analysis [47].
ACV and excoecarianin were dissolved in dimethyl sul-
foxide (DMSO) and then diluted with sterile de-ionized dis-
tilledwaterbefore use.Theﬁnal concentrationofDMSOwas
<0.1%,which was not toxicto Vero cells as shown previously
[44]. A 0.1% DMSO solution was included as control during
the experiments.
2.3. Cell and Viruses. African green monkey kidney cells
(Vero) (ATCC CCR-81) were used for antiviral assays. Vero
cells were propagated in DMEM (Gibco, Invitrogen, USA)
containing 5% of fetal calf serum (FCS). HSV-1 KOS strain






















































Figure 1: Chemical structure of excoecarianin.
titer was determined by plaque assay according to previously
described procedures [48] and was expressed as plaque
forming units (pfu) per milliliter. Virus stocks were stored at
–80◦Cu n t i lu s e .
2.4.CytotoxicAssay. Excoecarianin was tested forits cytotox-
ic eﬀect on Vero cells by XTT (Sodium 3 -[1-(phenylamino-
carbonyl)-3, 4-tetrazolium]-bis (4-methoxy-6-nitro) ben-
zene sulfonic acid) (Sigma-Aldrich, USA) assay as described
previously [45]. Brieﬂy, Vero cells were seeded onto 96-well
culture plates (Falcon, BD Biosciences, USA) at 1 × 104 cells
per well. After 4 h of incubation to allow the cells to settle,
excoecarianin was added into each well at various concentra-
tions.Theplatewasthenincubatedat37◦Cinanatm os pher e
of 5% CO2 for 72h. Later, the medium was discarded,
and the cells were subsequently washed with phosphate
buﬀered saline (PBS). The XTT reagent at a concentration
of 300μg/mL was added, and the plate was re-incubated
at 37◦C for an additional 2h to allow the development of
formazan. The optical densities (ODs) were then measured
with enzyme immunoassay (EIA) reader (Lab Systems MTX
Labs, USA) at a test wavelength of 492nm and a referenceEvidence-Based Complementary and Alternative Medicine 3
wavelength of 690nm. The cytotoxic eﬀect of excoecarianin
on Vero cells was evaluated according to the OD readings
obtained and the 50% cytotoxic concentration (CC50)w a s
calculated as previously described [45, 46]. Besides cytotoxic
cell death, Vero cells were also monitored in the presence of
excoecarianin for changes in cellular morphology for up to 7
days.
2.5. Antiviral Assay. The inhibitory eﬀect of excoecarianin
on HSV infection was investigated by plaque reduction assay
[49]. Vero cells were seeded onto 24-well culture plates
(Falcon,BDBiosciences,USA)atadensityof1 ×105 cellsper
well and incubated for 48 h to reach at least 95% conﬂuency.
The medium was then aspirated, and the cell monolayer
was infected with 100 pfu of HSV-1 or HSV-2 in the
absence or presence of excoecarianin. After 1h incubation
to allow virus adsorption, the cell monolayer was overlaid
with overlay medium containing 1% of methylcellulose. The
plate was further incubated at 37◦Ci na na t m o s p h e r eo f5 %
CO2 for 48h. Later, the overlay medium was removed, and
the infected cell monolayer was ﬁxed with 10% formalin.
The cell monolayer was then stained with 1% crystal
violet. The fraction of percent inhibition in inhibiting HSV
infection was determined, and the minimal concentration
that inhibited the formation of virus plaque number by 50%
(IC50) was calculated [49].
2.6. Time-of-Addition Study. The time-of-addition eﬀect of
excoecarianin was examined according to the previously
described procedures with some modiﬁcations [49]. Brieﬂy,
Vero cells were seeded onto 24-well culture plates (Falcon,
BD Biosciences, USA) at a density of 1 × 105 cells per well
and incubated for 48h to reach at least 95% conﬂuency.
Excoecarianin, at concentration of 1.5μM, was then added
onto the cells at either before (–6 and –2h), during (0h) or
after (2, and 4h) HSV-2 infection times. For pre-infection
(–6 and –2h), cells were washed thrice by PBS to eliminate
excoecarianin prior to the inoculation of the virus. Similar
procedures as described in “antiviral assay” of Section 2 were
carried to assess the virus plaques formed.
2.7. Viral Inactivation Assay. The direct eﬀect of excoecari-
anin on HSV-2 infectivity was evaluated according to pre-
viously described procedures [50] with some modiﬁcations.
Brieﬂy, diﬀerent concentrations (0.1, 0.5, 1.0, 1.5, 2.0, 2.5,
and 4.0μM) of excoecarianin were mixed thoroughly with 1
× 105 pfu ofHSV-2. The mixture was thenincubatedat 37◦C
for 6h. After the incubation, the mixture was diluted at least
100-fold and the residual virus infectivity was determined by
plaque assay as described earlier.
2.8. Combined Treatment of ACV and Excoecarianin in Inhib-
iting HSV-2 Infection. The antiviral activity of excoecarianin
in combination with ACV against HSV-2 was evaluated as
described previously with some modiﬁcations [51–54]. The
XTT assay was conducted as described above except that
HSV-2 at multiplicity of infection (moi) of 1.0 was added
concurrently with excoecarianin to the Vero cell monolayer.
Inhibitory eﬀectfromthecombinationofACVandexcoecar-
ianin against HSV-2 infection was analyzed by using the
isobologram method. The IC50 was used to calculate the
fractional inhibitory concentration (FIC) according to the
formula that previously shown [51–54]. The interaction
between excoecarianin and ACV was interpreted according
to the combined FIC index (FIC of excoecarianin plus FIC
of ACV). When the combined FIC index is equal to 1, the
combination is assumed to act in an additive manner; when
it is <1 the interaction is synergistic; and when the combined
FIC index is >1 the interaction is antagonistic.
2.9. Statistical Analysis. Data are presented as mean ± SD of
three independent experiments. The IC50 and CC50 values
were calculated by Microsoft Excel 2003. The signiﬁcance
between the test sample and solvent control was analyzed by
one-way analysis of variance (ANOVA) followed by Scheﬀe
multiple comparison test. A P value < .05 was considered to
be statistically signiﬁcant.
3.Results
3.1.Cytotoxicityof Excoecarianin on VeroCells. The cytotoxic
eﬀect of excoecarianin toward Vero cells was investigated
by the XTT method. Excoecarianin exhibited cytotoxic
eﬀect toward Vero cells in a concentration-dependent man-
ner (Figure 2) with only 11.57% of cells surviving after
treatment at 50μM( P < .05), but at least 75.2% and
95.4% cells remained alive at concentrations of 5.0 and
1.0μM, respectively. The CC50 of excoecarianin was 28.0 ±
2.6μM. No signiﬁcant changes in cellular morphology were
observed in excoecarianin-treated cells at a concentration
of 3μMa n dl o w e r( Figure 3). Overall, the results indicated
that excoecarianin showed little cytotoxic eﬀect at concen-
trations <5.0μM, and therefore, subsequent studies were
performed with excoecarianin treatment at concentrations
<5.0μM.
3.2. Antiviral Activity of Excoecarianin against HSV-1 and
HSV-2 Infection. The anti-HSV-1 and HSV-2 activities of
excoecarianin were evaluated by plaque reduction assay.
Excoecarianin inhibited HSV-2 infection in a concentration-
dependent manner (FIgure 4). The percentage of inhibition
were 0.02 ± 0.02%, 18.3 ± 8.5%, 20.0 ± 1.5%, 56.2 ±
7.3%, 62.8 ± 11.0%, 71.4 ± 11.9% and 77.5 ± 10.8%
at the concentrations of 0.1, 0.5, 1.0, 1.5, 2.0, 2.5, and
4.0μM, respectively. The IC50 of excoecarianin against HSV-
2 infection was determined to be 1.4 ± 0.1μM. When
tested against HSV-1 infection, excoecarianin was not able
to suppress HSV-1 infection (data not shown). At the
highest concentration used (4.0μM), excoecarianin could
only inhibit 11% of HSV-1 infection.
The selectivity index (SI) measures the safety of a com-
pound to be used as antiviral agent and also conﬁrms that
the antiviral eﬀect of a compound is not related to its toxic
eﬀect on the cell, is calculated by dividing the CC50 with the
IC50 valueofthe test compound.The SIof excoecarianin was



























Figure 2: The cytotoxic eﬀect of excoecarianin (open bars) and ACV (dotted bars) toward Vero cells as determined by XTT assay. Various
concentrations of excoecarianin or ACV were added to Vero cells. After 72h of incubation, the XTT solutionwas added and then the optical
densities were measured. The cytotoxic eﬀect of excoecarianin and ACV were evaluated and the 50% cytotoxic concentration (CC50)w a s
calculated. Each bar represents the mean ± SD of three independent experiments. The asterisk indicates signiﬁcant diﬀerence between test
sample and solvent control (P < .05).
Control
(a)
Treated with 40 µMA C V
(b)
Treated with 1.5 µM excoecarianin
(c)
Treated with 3 µM excoecarianin
(d)
Figure 3: The morphology of Vero cells without treatment (a) and with treatment of ACV (b) or excoecarianin (c)-(d). Vero cells were
seeded onto 24-well culture plates at density of 1 × 103 cells per well. After 4h, excoecarianin or ACV was added. The cells were incubated
for 7 days, and the cellular morphology was examined under phase-contrast microscope.
3.3. Antiviral Activity of Excoecarianin at Diﬀerent Times of
Addition. To study the inhibitory eﬀect of excoecarianin on
the stage of HSV-2 infection, the compound was added at
diﬀerentperiods(before,duringandafter)ofvirusinfection.
Results showed that excoecarianin added at 2 or 6h prior
to virus infection, and then being removed by PBS washes
beforetheinfection,didnothaveanyantiviral activity. When
added concurrently with HSV-2, excoecarianin, at concen-
tration of 1.5μM, inhibited 56.2% of virus infection. The
inhibitory rate, however, declined to 22.6 and 31.2% when
added at 2 and 4h after infection, respectively (Table 1). This







































Figure 4:Inhibitory eﬀect ofexcoecarianin (openbars) andACV(dotted bars) againstHSV-2infectionin Vero cell as determined by plaque
reduction assay. Vero cells were incubated with 100pfu of HSV-2 and diﬀerent concentrations of excoecarianin or ACV. After 1h, an overlay
medium containing1% methylcellulose wasadded. On Day 3 post-infection, the cell monolayerwas stained with crystalviolet and the virus
plaques formed were counted. The percentage of inhibitionwas calculated by comparing the plaque number of compound-treated group to
that of the untreated group. The concentrations of excoecarianin and ACV that inhibited 50% of HSV-2 infection (IC50) were determined.
Each bar represents the mean ± SD of three independent experiments. The asterisk indicates signiﬁcant diﬀerence between test sample and
solvent control (P < .05).
Table 1: The eﬀect of treatment time on the antiviral activity of
excoecarianin.
Time periods of compound addition Percentage of inhibition
Excoecarianin ACV
Before infection
–6 0.0 ± 0.0 0.0 ± 0.0
–2 0.0 ± 0.0 15.0 ± 7.6
During infection
0 56.2 ± 7.3∗ 95.4 ± 1.7∗
After infection
2 22.6 ± 10.2 92.6 ± 5.0∗
4 31.2 ± 19.2 94.9 ± 4.7∗
Excoecarianin and ACV were tested at a concentration of 1.5 and 5μM,
respectively; Data were mean ± SD of three independent experiments; ∗P
< .05 (compared between control and tested compound).
HSV-2 infection only when it is present at the time of the
infection, suggesting its antiviral activity is likely to be at the
viral entry stage.
3.4. Mechanism of Action of Excoecarianin against HSV-2 In-
fection. To investigate whetherexcoecarianin inhibitedHSV-
2 through inactivation of viral particles, a suspension of
the virus was treated at 37◦C for 6h with various concen-
trations of excoecarianin. The residual viral infectivity was
determined by plaque assay. As shown in Table 2,e x c o e c a r i -
anin inactivated viral infectivity in concentration-dependent
manner. While it did not inactivate HSV-2 at concentration
of ≤1.0μM, the residual viral infectivity gradually declined
from 61.3 ± 7.8%, to 27.7 ± 7.9%, and to 36.3 ± 10.8%





Control 0 100.0 ± 0.0
Excoecarianin 0.1 91.6 ± 7.4
0.5 98.8 ± 2.1
1.0 96.2 ± 6.6
1.5 61.3 ± 7.8∗
2.0 27.7 ± 7.9∗
2.5 36.3 ± 10.8∗
4.0 1.5 ± 0.1∗
ACV
0.5 100.0 ± 0.5
2.5 92.8 ± 6.5
5.0 92.9 ± 4.9
10.0 91.7 ± 8.2
Excoecarianin was mixed with HSV-2 at 37◦Cf o r6hb e f o r et h er e s i d u a l
viral titer was determined by plaque assay; Values were mean ± SD of three
independent experiments; ∗P < .05 (compared between control and tested
compound).
as the concentrations of excoecarianin increased from 1.5,
to 2.0, and to 2.5μM, respectively. Excoecarianin drastically
reduced viral infectivity at concentration of 4.0μMw i t h
only 1.5 ± 0.1% of virus being able to produce infectivity
(P < .05). In contrast, ACV, a well-deﬁned anti-HSV-2
agent which speciﬁcally inhibits viral DNA synthesis, did
not have eﬀect on virus infectivity even at a concentration of



















Figure 5: Synergistic antiviral activity of ACV and excoecarianin in
Vero cells. IC50 values were derived from the data shown in Table 3
andused to constructthe isobologram.FIC50 ofACVrepresents the
ratioof the IC50 ofACV in the presence of a constantconcentration
of excoecarianin to the IC50 of ACV alone. The x-axis represents
the ratio of the ﬁxed concentration of excoecarianin to the IC50
of excoecarianin alone. In this representation, displacement of
the experimental data points to the left of the theoretical line is
indicative of synergistic behavior.
3.5. Combined Treatment of ACV and Excoecarianin against
HSV-2Infection. The inhibitory eﬀectofACVplusexcoecar-
ianin against HSV-2 infection in Vero cells was examined by
XTT assay. The inhibitory activity was further evaluated by
the isobologram method. Low concentrations of ACV could
inhibit HSV-2 infection by the addition of excoecarianin
(Table 3).TheIC50 valueforACVcouldbereducedfrom1.33
± 0.84μM of ACV alone to 0.76 ± 0.34, 0.39 ± 0.18 and 0.11
± 0.02μM of ACV plus 1.0, 2.5 and 4.0μMo fe x c o e c a r i a n i n ,
respectively. The FICs of ACV plus excoecarianin were in
the range 0.50–0.66, indicating that the combinatorial eﬀect
of ACV plus excoecarianin in inhibiting HSV-2 infection
was synergistic (Table 3 and Figure 5). None of these drug
combinations exhibited cytotoxic eﬀect against Vero cells




HSV-2 infection but not HSV-1 infection. This antiviral
eﬀect was not correlated to cellular cytotoxicity as the
eﬀective micromolar concentrations of excoecarianin used
did not aﬀect cell viability (Figure 2) or induce changes in
cellular morphology (Figure 3). The antiviral activity was
most prominent when excoecarianin was added during viral
infection. This eﬀect was attributed to the compound’s
ability to directly reduce viral infectivity through interaction
with HSV-2 viral particles. In addition, combined treatment
Table 3: Inhibitory eﬀects of excoecarianin in combination with









alone 11.87 ± 2.9 — —
ACV alone 1.33 ± 0.84 — —
ACV + 1.0μM
excoecarianin 0.76 ± 0.34 0.66 synergistic
ACV + 2.5μM
excoecarianin 0.39 ± 0.18 0.51 synergistic
ACV + 5.0μM
excoecarianin 0.11 ± 0.02 0.50 synergistic
aResults are based on three independent experiments; bFICexcoecarianin and
FICACV are the fractional inhibitory concentration (FIC) of excoecarianin
and ACV, respectively.
of ACV and excoecarianin synergistically inhibited HSV-2
infection.
Our time-point assessment of antiviral activity indicated
thatexcoecarianin mosteﬀectivelyinhibitedHSV-2infection
only when it was concurrently present with the virus at
the time of infection, but was less eﬀective when cells
were pre-treated with it (and washed) or treated post viral
entry. Since our pre-treatment protocol involved washing
the compound oﬀ prior to infection, these results would
speculate thatexcoecarianin probablydoesnotpreventHSV-
2 infection by masking cell surface HSV-2 receptors through
covalent bonds formation to remain attached, nor does it
trigger any cellular antiviral responses including induction
of type I interferons to control the viral infection. Clearly,
excoecarianin is aﬀecting the early stage of HSV-2 infection
and the presence of the drug at the time of the infection is
crucial.TheobservationsuggeststhattheinhibitiononHSV-
2 by excoecarianin was most likely mediated by interfering
with virus entry step without having any direct eﬀect on the
cell itself, and indeed it was conﬁrmed by our subsequent
data that excoecarianin directly inactivated HSV-2 particles
(Table 2). This eﬀect is diﬀerent from that of ACV, which
acts as an inhibitor of HSV DNA synthesis. The ability of
excoecarianin to inactivate HSV-2 virus particles thus makes
it useful as an anti-HSV-2 agent in preventing de novo viral
infection and thereby could help control viral spread and
limit recurrent infections.
Invirustaxonomy,HSV-1andHSV-2aremembersofthe
genera Simplexvirus from the subfamily Alphaherpesvirinae
in Herpesviridae family [55]. Both viruses are sensitive to
nucleoside-like drugs, such as ACV. The eﬀectiveness on
inhibiting HSV-2 but not HSV-1 infection suggested that
excoecarianin is speciﬁc in mediating its anti-HSV activity.
As HSV-1 and HSV-2 virions share high degree of similarity,
it is unclear at the moment how excoecarianin is speciﬁc
only to HSV-2. Excoecarianin could possibly be speciﬁc to
viral glycoproteins expressed by HSV-2 such as glycoprotein
C (gC-2) which has been shown to contribute to serotype
diﬀerences in cell tropism and may play a diﬀerent role
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Figure 6: The time-of-addition eﬀect of excoecarianin against HSV-2 infection. Excoecarianin added prior to virus infection and then
washed out did not protect the cells from HSV-2 infection. The addition of excoecarianin after 2h of the virus inoculation also did not
inhibit HSV-2 infection. The compound can inhibit HSV-2 infection only when it was added concurrently with the virus infection.
studies are required to clarify the underlying reason(s) of the
selectivity in anti-HSV eﬀects mediated by excoecarianin.
Our previous studies also revealed that the acetone ex-
tract and severalpure compounds found inthe extracts from
P. urinaria could inhibit HSV-2 infection at diﬀerent magni-
tudesofpotency [44–46]. Particularly, we have observed that
the acetone extract of P. urinaria inhibited HSV-2 infection
through diminishing the virus infectivity, and the acetone
extract was only active in inhibiting HSV-2 when added
concurrently with the virus [44]. The acetone extract also
did not have any direct eﬀect on the cells in preventing
viral infection as indicated by a lack of beneﬁt from pre-
treatment dosage [44]. Based on our current experimental
observations, the acetone-isolated excoecarianin from P.
urinaria is likely responsible, at least in part, for the previous
antiviraleﬀectsobservedfromtheP.urinaria acetoneextract.
Furthermore, the identiﬁcation of excoecarianin as a speciﬁc
HSV-2 entry inhibitor by our study suggests that excoecar-
ianin or the standardized acetone extract P. urinaria could
both be explored for therapeutic development against HSV-
2i n f e c t i o n .A sP. urinaria also possesses antiviral activity
against other viruses as well, including hepatitis B virus
[37–41], retrovirus [42] and Epstein-Barr virus [43], it is
unclear whether excoecarianin can mediate similar antiviral
activities against other viruses. It would also be interesting to
investigate whether excoecarianin orthestandardized extract
could improve the disease pathogenesis in viral co-infection
cases such as in immunocompromised patients as an adjunct
therapy.
We have demonstrated here that the combined treatment
of ACV and excoecarianin exhibits synergistic activity in
inhibiting HSV-2 infection, decreasing the concentration
required for ACV to attain similar antiviral proﬁle. This
result has clinical signiﬁcance in the management of HSV-2
infection. As there are more ACV-resistant HSV related cases
being identiﬁed from immunocompromised patients as a
result of the emergence of HIV or organ transplantation
[6, 7, 58], anti-HSV agents targeting viral enzymes or
factors essential for entry will likely be useful for controlling
nucleoside-resistant strains [59]. The application of excoe-
carianinwouldcomplementACVtreatment,notonlyinlow-
ering the amount of drug necessary to achieve viral eradica-
tion but would also help decrease the risk of ACV-resistance
from occurring. Thus, the diﬀerence in mechanism of action
between excoecarianin and ACV, along with the synergistic
eﬀect observed from their combined treatment, implies that8 Evidence-Based Complementary and Alternative Medicine
excoecarianin could be useful in therapy against HSV-2 in-
fection in immunocompromised patients.
I ns ummary ,w eha v eidentiﬁedtheac et one-e xtract ede x-
coecarianin from P. urinaria as an antiviral compound that
is speciﬁc for HSV-2, which may be responsible in part for
the previously observed P. urinaria’s antiviral eﬀect against
this viral infection. The ability of excoecarianin to inactivate
HSV-2 virus particles and to act synergistically with the
nucleoside analogue ACV may make it useful to control viral
spread in de novo and recurrent infections. We therefore
suggest that the development of excoecarianin or the stan-
dardized extract of P. urinaria as an oral agent or as a topical
cream may be further investigated as an eﬀective strategy in
managing HSV-2 infections.
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